Patents Assigned to PharmaStem Therapeutics, Inc.
  • Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
    Patent number: 6605275
    Abstract: The present invention relates to hematopoietic stem and progenitor cells of neonatal or fetal blood that are cryopreserved, and the therapeutic uses of such stem and progenitor cells upon thawing. In particular, the present invention relates to the therapeutic use of fetal or neonatal stem cells for hematopoietic (or immune) reconstitution. Hematopoietic reconstitution with the cells of the invention can be valuable in the treatment or prevention of various diseases and disorders such as anemias, malignancies, autoimmune disorders, and various immune dysfunctions and deficiencies. In another embodiment, fetal or neonatal hematopoietic stem and progenitor cells which contain a heterologous gene sequence can be used for hematopoietic reconstitution in gene therapy. In a preferred embodiment of the invention, neonatal or fetal blood cells that have been cryopreserved and thawed can be used for autologous (self) reconstitution.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: August 12, 2003
    Assignee: PharmaStem Therapeutics, Inc.
    Inventors: Edward A. Boyse, Hal E. Broxmeyer, Gordon W. Douglas
  • Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
    Patent number: 6569427
    Abstract: The present invention relates to hematopoietic stem and progenitor cells of neonatal or fetal blood that are cryopreserved, and the therapeutic uses of such stem and progenitor cells upon thawing. In particular, the present invention relates to the therapeutic use of fetal or neonatal stem cells for hematopoietic (or immune) reconstitution. Hematopoietic reconstitution with the cells of the invention can be valuable in the treatment or prevention of various diseases and disorders such as anemias, malignancies, autoimmune disorders, and various immune dysfunctions and deficiencies. In another embodiment, fetal or neonatal hematopoietic stem and progenitor cells which contain a heterologous gene sequence can be used for hematopoietic reconstitution in gene therapy. In a preferred embodiment of the invention, neonatal or fetal blood cells that have been cryopreserved and thawed can be used for autologous (self) reconstitution.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: May 27, 2003
    Assignee: PharmaStem Therapeutics, Inc.
    Inventors: Edward A. Boyse, Hal E. Broxmeyer, Gordon W. Douglas
  • Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
    Patent number: 6461645
    Abstract: The present invention relates to hematopoietic stem and progenitor cells of neonatal or fetal blood that are cryopreserved, and the therapeutic uses of such stem and progenitor cells upon thawing. In particular, the present invention relates to the therapeutic use of fetal or neonatal stem cells for hematopoietic (or immune) reconstitution. Hematopoietic reconstitution with the cells of the invention can be valuable in the treatment or prevention of various diseases and disorders such as anemias, malignancies, autoimmune disorders, and various immune dysfunctions and deficiencies. In another embodiment, fetal or neonatal hematopoietic stem and progenitor cells which contain a heterologous gene sequence can be used for hematopoietic reconstitution in gene therapy. In a preferred embodiment of the invention, neonatal or fetal blood cells that have been cryopreserved and thawed can be used for autologous (self) reconstitution.
    Type: Grant
    Filed: May 16, 1990
    Date of Patent: October 8, 2002
    Assignee: PharmaStem Therapeutics, Inc.
    Inventors: Edward A. Boyse, Hal E. Broxmeyer, Gordon W. Douglas